TM Editors' Note: This article discusses penny stocks and/or microcaps. Such stocks are readily manipulated; do your own careful due diligence. 

41 psychedelic drug stocks trade on the various North American stock exchanges and in the past week 24 went up, 12 went down and 5 had no change in price. 

The 41 stocks consist of:

• 7 micro-cap stocks (Group #1) with an average market capitalization of $197M,
• 2 small-cap stocks (Group #2) with an average market capitalization of $1.2B,
• 32 nano-cap stocks (Group #3) with an average market capitalization of just $33M.

Below is the stock price performance for each Group for the week ending April 23rd with the extent of their movement since the end of February shown in brackets:

Group #1

The 7 stocks in Group #1:

• have market capitalizations ranging from $104M to $315M and average $197M
• advanced 7.1% (+8.6% in the last 8 weeks) and
• are constituents in the munKNEE Pure-Play Psychedelic Drug Stocks Index as their market capitalizations are more than $100M and less than $1B.

The performance of the Group #1 constituents last week were, in descending order (with the last 8 weeks in brackets), as follows :

1. Jaguar (JAGX): +24.6% (-22.9%) to $1.62/share 
2. Bionomics (BNOEF): +20.0% (-45.5%) to $0.18/share
3. Numinus (LKYSF): +19.4% (-27.7%) to $0.86/share
4. Seelos (SEEL): +18.8% (+110.4%) to $6.25/share
5. Revive (RVVTF): +8.8% (-7.5%) to $0.37/share
6. Field Trip (FTRPF): -8.1% (-20.0%) to $4.43/share
7. Cybin (CLXPF): -9.3% (N/C) to $1.27/share

Group #2

The two stocks in Group #2:

• have market capitalizations of $920M and $1.4B
• advanced 6.2% (-16.8% in the last 8 weeks) as follows:
  1. Compass Pathways (CMPS): +2.8% (-21.8%) to $35.30/share
  2. Mind Medicine (MMEDF): +44.9% (+6.0%) to $3.52/share

The above two stocks are not eligible for inclusion in the munKNEE Pure-Play Psychedelic Drug Stocks Index as their market capitalizations are so large that their inclusion would skew the performance results of the index so are reported above separately.

Group #3

The 32 stocks in Group #3:

• have market capitalizations ranging from just $3M to $75M and average $33M
• advanced 7.1% (-26.0% in the last 8 weeks) with 17 going up in price, 10 going down, and 5 having no change in price and are, in alphabetical order, as follows:
  • Aion, Algernon, Bright Minds, Champignon, Codebase, Core One, Ehave, Entheon, Graph Blockchain, Havn, Hollister, Lobe Sciences, M2BIO, Mind Cure, Mindset, Mydecine, Neonmind, Newscope-PharmaTher, New Wave, Nova Mentis, Novamind,  Nutritional High, Optimi, PayBio, Psyched Wellness, Pysence, Pure Extracts, Red Light, Silo Wellness, SILO Pharma, Tryp and Thoughtful Brands.

The above 32 stocks are not eligible for inclusion in the munKNEE Pure-Play Psychedelic Drug Stocks Index as their market capitalizations are less than $100M.

In Summary

• The 7 stocks in Group #1 have market capitalizations ranging from $104M to $315M (an average $197M) and they advanced 7.1% last week and are UP 8.6% since the end of February (8 weeks).

• The two stocks in Group #2 have market capitalizations of $920M and $1.4B and they advanced 6.2% last week but are DOWN -16.8% in the last 8 weeks.

• The 32 stocks in Group #3 have market capitalizations ranging from just $3M to $75M (an average $33M) and they advanced 7.1% last week but are DOWN -26.0% in the last 8 weeks.

Cannabis & Cannabis-related Index Performance Comparisons

In addition to tracking the performance of pure-play psychedelic drug stocks (and pure-play plant-based food stocks) munKNEE.com also tracks the performance of five (5) cannabis categories and below is a comparison of how each of those indices have performed YTD, and so far in April in brackets, which we think provides the clearest overview of the cannabis stock sector that is available anywhere:

1. the Canadian Pure-Play Licensed Producers Pot Stock Index (8 constituents): +36.7% YTD (-17.0% so far in April); Beta: 2.11 (See index details here.)
2. the American Pure-Play Multi-State Operators Pot Stock Index (22 constituents): +28.7% YTD; (-7.6% so far in April); Beta: 2.69
3. the Ancillary Pot Stocks Index (16 constituents): +12.3% YTD; (-4.4% so far in April); Beta: 2.2
4. the Conservative Pot Stocks Index (8 constituents): +6.3% YTD; (+3.0% so far in April); Beta: 0.96 and
5. the new Cannabis-Centric Bio-Pharma Companies Index (13 constituents): -1.1% YTD; (-14.1% so far in April); Beta: 2.9. (See details of the index here.)

The above 5 non-tradable indices and the Pure-Play Psychedelic Drug Stocks Index replicate the performance of a portfolio investing an equal amount of money in each company in the various cannabis categories, with daily rebalancing to maintain an equal weight, to serve as benchmarks to measure the performance of individual stocks compared to their respective index. 

(For more information on the reason(s) behind the changes outlined below you are urged to click on the stock symbols provided by TalkMarkets, where additional information is provided. All currency amounts are in U.S. dollars. Go here to convert to another currency.)